44 related articles for article (PubMed ID: 38597264)
1. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
[TBL] [Abstract][Full Text] [Related]
2. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
Beekman AM; O'Connell MA; Howell LA
ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
[TBL] [Abstract][Full Text] [Related]
3. Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1.
Beekman AM; Howell LA
ChemMedChem; 2016 Apr; 11(8):802-13. PubMed ID: 26696548
[TBL] [Abstract][Full Text] [Related]
4. Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin.
Zhao B; Sensintaffar J; Bian Z; Belmar J; Lee T; Olejniczak ET; Fesik SW
Bioorg Med Chem; 2017 Jun; 25(12):3087-3092. PubMed ID: 28428041
[TBL] [Abstract][Full Text] [Related]
5. MCL-1 inhibitors - where are we now (2019)?
Fletcher S
Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
[No Abstract] [Full Text] [Related]
6. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
[TBL] [Abstract][Full Text] [Related]
7. Development of Mcl-1 inhibitors for cancer therapy.
Negi A; Murphy PV
Eur J Med Chem; 2021 Jan; 210():113038. PubMed ID: 33333396
[TBL] [Abstract][Full Text] [Related]
8. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract][Full Text] [Related]
9. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
[TBL] [Abstract][Full Text] [Related]
10. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]